Altimmune, Inc. (ALT) — 10-Q Filings

10-Q Filings (6)

• Altimmune Narrows Q3 Loss on R&D Cuts, Boosts Cash with Equity & Debt — Nov 6, 2025 Risk: medium
  Altimmune, Inc. (ALT) reported a net loss of $19.014 million for the three months ended September 30, 2025, an improvement from a net loss of $22.845 million in
• Altimmune's Q2 Loss Widens to $35M Amid Continued ATM Offerings — Aug 12, 2025 Risk: high
  Altimmune, Inc. reported a net loss of $35.0 million for the three months ended June 30, 2025, compared to a net loss of $30.0 million for the same period in 20
• Altimmune Q1 2025: Assets $77.8M, Liabilities $72.4M — May 13, 2025 Risk: medium
  Altimmune, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported total assets of $77.8 million and total liabilities of $72
• Altimmune Q3 2024: Equity and Financial Disclosures — Nov 12, 2024 Risk: medium
  Altimmune, Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial statements show significant changes in equi
• Altimmune Reports Q2 2024 Results: Revenue Up, Net Loss Widens — Aug 8, 2024 Risk: medium
  Altimmune, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $71.05 million and total liabilities of $70.68 million
• Altimmune, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
  Altimmune, Inc. (ALT) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Altimmune, Inc. filed a 10-Q report for the period ending March 31, 2024. The

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX